Research programme: immuno-oncology therapies - Evotec/Ex Scientia

Drug Profile

Research programme: immuno-oncology therapies - Evotec/Ex Scientia

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator Evotec AG; Ex Scientia
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 06 Jul 2016 Evotec in-licenses CRISPR-Cas9 technology from Broad Institute of MIT and Harvard
  • 26 Apr 2016 Early research in Cancer in France (unspecified route)
  • 26 Apr 2016 Evotec and Ex Scientia enter into a collaboration to discover and develop bispecific small molecule immuno-oncology therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top